APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Vaccine for Tumor

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Peptide Vaccine for Tumor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025181 pages

Choose your research edition.

Industry ResearchPeptide Vaccine for Tumor Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Vaccine for Tumor Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Peptide Vaccine for Tumor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Vaccine for Tumor Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Vaccine for Tumor Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Peptide Vaccine for Tumor market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Peptide Vaccine for Tumor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide Vaccine for Tumor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide Vaccine for Tumor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Peptide Vaccine for Tumor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Peptide Vaccine for Tumor include AmbioPharm, Ultimovacs, Sellas Life Sciences, OncoPep, Marker Therapeutics, Inc., Immatics, Anergis, Almac and ACT, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peptide Vaccine for Tumor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide Vaccine for Tumor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide Vaccine for Tumor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peptide Vaccine for Tumor market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide Vaccine for Tumor Segment by Company

AmbioPharm

Ultimovacs

Sellas Life Sciences

OncoPep

Marker Therapeutics, Inc.

Immatics

Anergis

Almac

ACT

Peptide Vaccine for Tumor Segment by Type

Recombinant Polypeptide Vaccine

Synthetic Polypeptide Vaccines

Others

Peptide Vaccine for Tumor Segment by Application

Infectious Disease Prevention

Cancer Immunotherapy

Others

Peptide Vaccine for Tumor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Vaccine for Tumor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Vaccine for Tumor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Vaccine for Tumor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide Vaccine for Tumor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Peptide Vaccine for Tumor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Peptide Vaccine for Tumor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Peptide Vaccine for Tumor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Peptide Vaccine for Tumor Industry Trends Table 2. Peptide Vaccine for Tumor Industry Drivers Table 3. Peptide Vaccine for Tumor Industry Opportunities and Challenges Table 4. Peptide Vaccine for Tumor Industry Restraints Table 5. Global Peptide Vaccine for Tumor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Peptide Vaccine for Tumor Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Peptide Vaccine for Tumor Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Peptide Vaccine for Tumor Sales Market Share by Manufacturers Table 9. Global Peptide Vaccine for Tumor Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Peptide Vaccine for Tumor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Peptide Vaccine for Tumor Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Peptide Vaccine for Tumor Manufacturers, Product Type & Application Table 13. Global Peptide Vaccine for Tumor Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Peptide Vaccine for Tumor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Recombinant Polypeptide Vaccine Table 17. Major Manufacturers of Synthetic Polypeptide Vaccines Table 18. Major Manufacturers of Others Table 19. Global Peptide Vaccine for Tumor Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Units) Table 21. Global Peptide Vaccine for Tumor Sales by Type (2027-2032) & (K Units) Table 22. Global Peptide Vaccine for Tumor Sales Market Share by Type (2021-2026) Table 23. Global Peptide Vaccine for Tumor Sales Market Share by Type (2027-2032) Table 24. Global Peptide Vaccine for Tumor Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Peptide Vaccine for Tumor Revenue by Type (2021-2026) & (K Units) Table 26. Global Peptide Vaccine for Tumor Revenue by Type (2027-2032) & (K Units) Table 27. Global Peptide Vaccine for Tumor Revenue Market Share by Type (2021-2026) Table 28. Global Peptide Vaccine for Tumor Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Infectious Disease Prevention Table 30. Major Manufacturers of Cancer Immunotherapy Table 31. Major Manufacturers of Others Table 32. Global Peptide Vaccine for Tumor Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Peptide Vaccine for Tumor Sales by Application (2021-2026) & (K Units) Table 34. Global Peptide Vaccine for Tumor Sales by Application (2027-2032) & (K Units) Table 35. Global Peptide Vaccine for Tumor Sales Market Share by Application (2021-2026) Table 36. Global Peptide Vaccine for Tumor Sales Market Share by Application (2027-2032) Table 37. Global Peptide Vaccine for Tumor Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Peptide Vaccine for Tumor Revenue by Application (2021-2026) & (K Units) Table 39. Global Peptide Vaccine for Tumor Revenue by Application (2027-2032) & (K Units) Table 40. Global Peptide Vaccine for Tumor Revenue Market Share by Application (2021-2026) Table 41. Global Peptide Vaccine for Tumor Revenue Market Share by Application (2027-2032) Table 42. Global Peptide Vaccine for Tumor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Peptide Vaccine for Tumor Sales by Region (2021-2026) & (K Units) Table 44. Global Peptide Vaccine for Tumor Sales Market Share by Region (2021-2026) Table 45. Global Peptide Vaccine for Tumor Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Peptide Vaccine for Tumor Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Peptide Vaccine for Tumor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Peptide Vaccine for Tumor Sales by Country (2021-2026) & (K Units) Table 49. North America Peptide Vaccine for Tumor Sales by Country (2027-2032) & (K Units) Table 50. Europe Peptide Vaccine for Tumor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Peptide Vaccine for Tumor Sales by Country (2021-2026) & (K Units) Table 52. Europe Peptide Vaccine for Tumor Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Peptide Vaccine for Tumor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Peptide Vaccine for Tumor Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Peptide Vaccine for Tumor Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Peptide Vaccine for Tumor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Peptide Vaccine for Tumor Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Peptide Vaccine for Tumor Sales by Country (2027-2032) & (K Units) Table 59. Global Peptide Vaccine for Tumor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Peptide Vaccine for Tumor Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Peptide Vaccine for Tumor Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Peptide Vaccine for Tumor Revenue Market Share by Region (2021-2026) Table 63. Global Peptide Vaccine for Tumor Revenue Market Share by Region (2027-2032) Table 64. AmbioPharm Company Information Table 65. AmbioPharm Business Overview Table 66. AmbioPharm Peptide Vaccine for Tumor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. AmbioPharm Peptide Vaccine for Tumor Product Portfolio Table 68. AmbioPharm Recent Development Table 69. Ultimovacs Company Information Table 70. Ultimovacs Business Overview Table 71. Ultimovacs Peptide Vaccine for Tumor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Ultimovacs Peptide Vaccine for Tumor Product Portfolio Table 73. Ultimovacs Recent Development Table 74. Sellas Life Sciences Company Information Table 75. Sellas Life Sciences Business Overview Table 76. Sellas Life Sciences Peptide Vaccine for Tumor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Sellas Life Sciences Peptide Vaccine for Tumor Product Portfolio Table 78. Sellas Life Sciences Recent Development Table 79. OncoPep Company Information Table 80. OncoPep Business Overview Table 81. OncoPep Peptide Vaccine for Tumor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. OncoPep Peptide Vaccine for Tumor Product Portfolio Table 83. OncoPep Recent Development Table 84. Marker Therapeutics, Inc. Company Information Table 85. Marker Therapeutics, Inc. Business Overview Table 86. Marker Therapeutics, Inc. Peptide Vaccine for Tumor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Marker Therapeutics, Inc. Peptide Vaccine for Tumor Product Portfolio Table 88. Marker Therapeutics, Inc. Recent Development Table 89. Immatics Company Information Table 90. Immatics Business Overview Table 91. Immatics Peptide Vaccine for Tumor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Immatics Peptide Vaccine for Tumor Product Portfolio Table 93. Immatics Recent Development Table 94. Anergis Company Information Table 95. Anergis Business Overview Table 96. Anergis Peptide Vaccine for Tumor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Anergis Peptide Vaccine for Tumor Product Portfolio Table 98. Anergis Recent Development Table 99. Almac Company Information Table 100. Almac Business Overview Table 101. Almac Peptide Vaccine for Tumor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Almac Peptide Vaccine for Tumor Product Portfolio Table 103. Almac Recent Development Table 104. ACT Company Information Table 105. ACT Business Overview Table 106. ACT Peptide Vaccine for Tumor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. ACT Peptide Vaccine for Tumor Product Portfolio Table 108. ACT Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. Peptide Vaccine for Tumor Distributors List Table 112. Peptide Vaccine for Tumor Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Peptide Vaccine for Tumor Product Image Figure 2. Global Peptide Vaccine for Tumor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Vaccine for Tumor Market Size (2021-2032) & (US$ Million) Figure 4. Global Peptide Vaccine for Tumor Sales (2021-2032) & (K Units) Figure 5. Global Peptide Vaccine for Tumor Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Peptide Vaccine for Tumor Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Recombinant Polypeptide Vaccine Image Figure 9. Synthetic Polypeptide Vaccines Image Figure 10. Others Image Figure 11. Global Peptide Vaccine for Tumor Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Peptide Vaccine for Tumor Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Peptide Vaccine for Tumor Sales Market Share by Type (2021-2032) Figure 14. Global Peptide Vaccine for Tumor Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Peptide Vaccine for Tumor Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Peptide Vaccine for Tumor Revenue Market Share by Type (2021-2032) Figure 17. Infectious Disease Prevention Image Figure 18. Cancer Immunotherapy Image Figure 19. Others Image Figure 20. Global Peptide Vaccine for Tumor Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Peptide Vaccine for Tumor Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Peptide Vaccine for Tumor Sales Market Share by Application (2021-2032) Figure 23. Global Peptide Vaccine for Tumor Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Peptide Vaccine for Tumor Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Peptide Vaccine for Tumor Revenue Market Share by Application (2021-2032) Figure 26. North America Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Peptide Vaccine for Tumor Sales Market Share by Country (2021-2032) Figure 28. U.S. Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Peptide Vaccine for Tumor Sales Market Share by Country (2021-2032) Figure 33. Germany Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Peptide Vaccine for Tumor Sales Market Share by Country (2021-2032) Figure 40. China Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Peptide Vaccine for Tumor Sales Market Share by Country (2021-2032) Figure 48. Brazil Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Peptide Vaccine for Tumor Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Peptide Vaccine for Tumor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Peptide Vaccine for Tumor Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Peptide Vaccine for Tumor Revenue (2021-2032) & (US$ Million) Figure 59. North America Peptide Vaccine for Tumor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Peptide Vaccine for Tumor Revenue (2021-2032) & (US$ Million) Figure 61. Europe Peptide Vaccine for Tumor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Peptide Vaccine for Tumor Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Peptide Vaccine for Tumor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Peptide Vaccine for Tumor Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Peptide Vaccine for Tumor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Peptide Vaccine for Tumor Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Peptide Vaccine for Tumor Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Polypeptide Vaccine
  • Synthetic Polypeptide Vaccines
  • Others
Applications
  • Infectious Disease Prevention
  • Cancer Immunotherapy
  • Others
Companies covered
  • AmbioPharm
  • Ultimovacs
  • Sellas Life Sciences
  • OncoPep
  • Marker Therapeutics, Inc.
  • Immatics
  • Anergis
  • Almac
  • ACT

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Peptide Vaccine for Tumor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Peptide Vaccine for Tumor Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Peptide Vaccine for Tumor Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Peptide Vaccine for Tumor Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Peptide Vaccine for Tumor Market Dynamics
  1. 2.1 Peptide Vaccine for Tumor Industry Trends
  2. 2.2 Peptide Vaccine for Tumor Industry Drivers
  3. 2.3 Peptide Vaccine for Tumor Industry Opportunities and Challenges
  4. 2.4 Peptide Vaccine for Tumor Industry Restraints
3 Peptide Vaccine for Tumor Market by Manufacturers
  1. 3.1 Global Peptide Vaccine for Tumor Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Peptide Vaccine for Tumor Sales by Manufacturers (2021-2026)
  3. 3.3 Global Peptide Vaccine for Tumor Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Peptide Vaccine for Tumor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Peptide Vaccine for Tumor Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Peptide Vaccine for Tumor Manufacturers, Product Type & Application
  7. 3.7 Global Peptide Vaccine for Tumor Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Peptide Vaccine for Tumor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Peptide Vaccine for Tumor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Peptide Vaccine for Tumor Tier 1, Tier 2, and Tier 3
4 Peptide Vaccine for Tumor Market by Type
  1. 4.1 Peptide Vaccine for Tumor Type Introduction
  2. 4.1.1 Recombinant Polypeptide Vaccine
  3. 4.1.2 Synthetic Polypeptide Vaccines
  4. 4.1.3 Others
  5. 4.2 Global Peptide Vaccine for Tumor Sales by Type
  6. 4.2.1 Global Peptide Vaccine for Tumor Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Peptide Vaccine for Tumor Sales by Type (2021-2032)
  8. 4.2.3 Global Peptide Vaccine for Tumor Sales Market Share by Type (2021-2032)
  9. 4.3 Global Peptide Vaccine for Tumor Revenue by Type
  10. 4.3.1 Global Peptide Vaccine for Tumor Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Peptide Vaccine for Tumor Revenue by Type (2021-2032)
  12. 4.3.3 Global Peptide Vaccine for Tumor Revenue Market Share by Type (2021-2032)
5 Peptide Vaccine for Tumor Market by Application
  1. 5.1 Peptide Vaccine for Tumor Application Introduction
  2. 5.1.1 Infectious Disease Prevention
  3. 5.1.2 Cancer Immunotherapy
  4. 5.1.3 Others
  5. 5.2 Global Peptide Vaccine for Tumor Sales by Application
  6. 5.2.1 Global Peptide Vaccine for Tumor Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peptide Vaccine for Tumor Sales by Application (2021-2032)
  8. 5.2.3 Global Peptide Vaccine for Tumor Sales Market Share by Application (2021-2032)
  9. 5.3 Global Peptide Vaccine for Tumor Revenue by Application
  10. 5.3.1 Global Peptide Vaccine for Tumor Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Peptide Vaccine for Tumor Revenue by Application (2021-2032)
  12. 5.3.3 Global Peptide Vaccine for Tumor Revenue Market Share by Application (2021-2032)
6 Global Peptide Vaccine for Tumor Sales by Region
  1. 6.1 Global Peptide Vaccine for Tumor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide Vaccine for Tumor Sales by Region (2021-2032)
  3. 6.2.1 Global Peptide Vaccine for Tumor Sales by Region (2021-2026)
  4. 6.2.2 Global Peptide Vaccine for Tumor Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Peptide Vaccine for Tumor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Peptide Vaccine for Tumor Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Peptide Vaccine for Tumor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Peptide Vaccine for Tumor Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Peptide Vaccine for Tumor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Peptide Vaccine for Tumor Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Peptide Vaccine for Tumor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Peptide Vaccine for Tumor Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Peptide Vaccine for Tumor Revenue by Region
  1. 7.1 Global Peptide Vaccine for Tumor Revenue by Region
  2. 7.1.1 Global Peptide Vaccine for Tumor Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Peptide Vaccine for Tumor Revenue by Region (2021-2026)
  4. 7.1.3 Global Peptide Vaccine for Tumor Revenue by Region (2027-2032)
  5. 7.1.4 Global Peptide Vaccine for Tumor Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Peptide Vaccine for Tumor Revenue (2021-2032)
  8. 7.2.2 North America Peptide Vaccine for Tumor Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Peptide Vaccine for Tumor Revenue (2021-2032)
  11. 7.3.2 Europe Peptide Vaccine for Tumor Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Peptide Vaccine for Tumor Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Peptide Vaccine for Tumor Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Peptide Vaccine for Tumor Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Peptide Vaccine for Tumor Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AmbioPharm
  2. 8.1.1 AmbioPharm Company Information
  3. 8.1.2 AmbioPharm Business Overview
  4. 8.1.3 AmbioPharm Peptide Vaccine for Tumor Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AmbioPharm Peptide Vaccine for Tumor Product Portfolio
  6. 8.1.5 AmbioPharm Recent Developments
  7. 8.2 Ultimovacs
  8. 8.2.1 Ultimovacs Company Information
  9. 8.2.2 Ultimovacs Business Overview
  10. 8.2.3 Ultimovacs Peptide Vaccine for Tumor Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ultimovacs Peptide Vaccine for Tumor Product Portfolio
  12. 8.2.5 Ultimovacs Recent Developments
  13. 8.3 Sellas Life Sciences
  14. 8.3.1 Sellas Life Sciences Company Information
  15. 8.3.2 Sellas Life Sciences Business Overview
  16. 8.3.3 Sellas Life Sciences Peptide Vaccine for Tumor Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sellas Life Sciences Peptide Vaccine for Tumor Product Portfolio
  18. 8.3.5 Sellas Life Sciences Recent Developments
  19. 8.4 OncoPep
  20. 8.4.1 OncoPep Company Information
  21. 8.4.2 OncoPep Business Overview
  22. 8.4.3 OncoPep Peptide Vaccine for Tumor Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 OncoPep Peptide Vaccine for Tumor Product Portfolio
  24. 8.4.5 OncoPep Recent Developments
  25. 8.5 Marker Therapeutics, Inc.
  26. 8.5.1 Marker Therapeutics, Inc. Company Information
  27. 8.5.2 Marker Therapeutics, Inc. Business Overview
  28. 8.5.3 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Product Portfolio
  30. 8.5.5 Marker Therapeutics, Inc. Recent Developments
  31. 8.6 Immatics
  32. 8.6.1 Immatics Company Information
  33. 8.6.2 Immatics Business Overview
  34. 8.6.3 Immatics Peptide Vaccine for Tumor Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Immatics Peptide Vaccine for Tumor Product Portfolio
  36. 8.6.5 Immatics Recent Developments
  37. 8.7 Anergis
  38. 8.7.1 Anergis Company Information
  39. 8.7.2 Anergis Business Overview
  40. 8.7.3 Anergis Peptide Vaccine for Tumor Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Anergis Peptide Vaccine for Tumor Product Portfolio
  42. 8.7.5 Anergis Recent Developments
  43. 8.8 Almac
  44. 8.8.1 Almac Company Information
  45. 8.8.2 Almac Business Overview
  46. 8.8.3 Almac Peptide Vaccine for Tumor Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Almac Peptide Vaccine for Tumor Product Portfolio
  48. 8.8.5 Almac Recent Developments
  49. 8.9 ACT
  50. 8.9.1 ACT Company Information
  51. 8.9.2 ACT Business Overview
  52. 8.9.3 ACT Peptide Vaccine for Tumor Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 ACT Peptide Vaccine for Tumor Product Portfolio
  54. 8.9.5 ACT Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peptide Vaccine for Tumor Value Chain Analysis
  2. 9.1.1 Peptide Vaccine for Tumor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peptide Vaccine for Tumor Production Mode & Process
  6. 9.2 Peptide Vaccine for Tumor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peptide Vaccine for Tumor Distributors
  9. 9.2.3 Peptide Vaccine for Tumor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst